Abstracts tagged "juvenile idiopathic arthritis (JIA) and treatment options"

Abstract Number: 2284 • 2017 ACR/ARHP Annual Meeting
Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Carlos Sánchez-Piedra¹, Rosa Rosello², Javier Manero³, M. Victoria Hernández⁴, Fernando Sánchez-Alonso⁵, Eduardo Cuende⁶, Blanca García Magallon³, Ana M. Ortiz Garcia⁷, Cesar Diaz-Torné⁸, Mercedes Freire⁹, Paloma Vela¹⁰, Raúl Menor Almagro¹¹, Agueda Prior¹², Federico Díaz-González¹³, Juan J. Gomez-Reino¹⁴ and Sagrario Bustabad¹⁵, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital San Jorge, Huesca, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁶University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ⁷Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁸GEACSER, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁰Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹¹Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹²Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹³Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁴Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁵Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The advent of new biological drugs has changed the prognosis and…
Abstract Number: 2291 • 2017 ACR/ARHP Annual Meeting
Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis: First Results of Clinical Outcome after 24 Months
Petra Hissink Muller^1,2, Danielle Brinkman^1,3, Dieneke Schonenberg-Meinema⁴, Yvonne Koopman-Keemink⁵, Wytse van den Bosch⁶, Isabel Brederije¹, Peter Bekkering⁷, Taco Kuijpers⁴, Marion van Rossum⁸, Lisette van Suijlekom-Smit², J Merlijn van den Berg⁴, CF Allaart⁹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Pediatrics, Alrijne Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Hematology, Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Pediatrics, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Department of Pediatrics, Haaglanden Medical Center, The Hague, Netherlands, ⁷Department of Physiotherapy, Prinses Maxima Pediatric Oncology Center, Utrecht, Netherlands, ⁸Department of Pediatric Rheumatology, Amsterdam Rheumatology and Immunology Center location Reade Amsterdam, Amsterdam, Netherlands, ⁹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The BeSt treatment strategy for children with juvenile idiopathic arthritis (JIA) has not been determined. The aim of the BeSt for Kids study was…
Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Rebecca Davies¹, Roberto Carrasco², Helen Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Yiannis Ioannou⁷, Lucy R. Wedderburn⁸, Wendy Thomson⁹, Kimme L. Hyrich¹⁰ and on Behalf Of Childhood Arthritis Prospective Study (CAPS)¹¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Newcastle University, Newcastle, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ¹⁰Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹¹university of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…
Abstract Number: 1172 • 2012 ACR/ARHP Annual Meeting
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
Charalampia Papadopoulou¹, Maria I. Gonzalez¹, Juan C. Nieto¹, Mikhail Kostik², Marek Bohm¹, Stefano Lanni¹, Valentina Muratore³, Alessandro Consolaro¹, Alberto Martini⁴ and Angelo Ravelli⁵, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁵University of Genova, Genova, Italy
Background/Purpose: Intra-articular corticosteroid injection (IACI) therapy in juvenile idiopathic arthritis (JIA) is generally considered for the treatment of children with arthritis in a small number…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].